Opus Genetics, Inc.'s SEC filings document financing, governance, capital-structure and operating disclosures for a Delaware clinical-stage biopharmaceutical company developing ophthalmic gene therapies. Form 8-K reports cover senior secured notes, preferred stock private placement activity, financial results, corporate presentations and compensatory arrangements.
Proxy materials and stockholder-vote reports cover director elections, auditor ratification, say-on-pay matters and amendments affecting authorized common stock. The filings also record corporate updates related to the company's inherited retinal disease pipeline and Phentolamine Ophthalmic Solution 0.75%.
Opus Genetics, Inc. President and director Benjamin R. Yerxa reported an equity award in the form of 400,000 shares of common stock on January 22, 2026. The filing shows the shares at a price of $0 per share, reflecting a grant rather than an open-market purchase. Following this transaction, he beneficially owns 719,005 shares of common stock directly. According to the footnote, the award represents restricted stock units that vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, conditioned on his continued service.
Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, received a grant of 250,000 shares of common stock in the form of restricted stock units on 01/22/2026. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, conditioned on his continuing service with the company. The grant was recorded at a price of $0 per share, reflecting that no cash payment is required from him for the award. Following this transaction, he beneficially owns 304,500 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. granted 86,500 shares of its common stock in the form of restricted stock units to executive Amy Zaremba Rabourn, who serves as Head of Fin. Quality Assurance. The grant was made on January 22, 2026 at a price of $0 per share, reflecting an equity award rather than a market purchase.
The restricted stock units vest in substantially equal quarterly installments on each anniversary of the grant date over the next sixteen quarters, as long as she continues in service. After this grant, she beneficially owns 193,128 shares of common stock directly.
Opus Genetics, Inc. Chief Executive Officer and director Magrath George reported an equity award of company common stock. On January 22, 2026, he received 483,639 shares of common stock at a price of $0 per share, described as a grant of restricted stock units. After this grant, he beneficially owned 1,775,293 shares of Opus Genetics common stock in direct ownership.
The restricted stock units vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, and vesting is conditioned on his continuing service.
Opus Genetics, Inc. reported an equity award to its Chief Scientific & Dev. Officer, Jayagopal Ashwath. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as a grant of restricted stock units. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, as long as he continues in service. Following this grant, he beneficially owns 525,807 shares of Opus Genetics common stock directly.
Opus Genetics, Inc. reported an equity award to its Chief Financial Officer, Robert E. Gagnon. On January 22, 2026, he received 400,000 shares of common stock at a price of $0 per share, reported as an acquisition. A footnote explains that this represents a grant of restricted stock units that vest in substantially equal quarterly installments on the anniversary of the grant date over the next 16 quarters, subject to his continuing service. Following this grant, Gagnon beneficially owned 600,000 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic share withholding related to equity compensation. On January 18, 2026, 3,390 shares of common stock were withheld by the company at a value of $2.10 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. After this withholding, she beneficially owned 106,628 shares of Opus Genetics common stock directly. The footnote clarifies this was not an open market sale of securities but a tax-related withholding by the issuer.
Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Fin. Quality Assurance, reported a share withholding related to equity compensation. On 01/10/2026, the issuer withheld 3,950 shares of common stock at $1.93 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. This was not an open market sale of securities, but an administrative tax withholding. After this transaction, Rabourn beneficially owned 110,018 shares of Opus Genetics common stock, held directly.
Opus Genetics, Inc. is highlighting its business at the 44th Annual J.P. Morgan Healthcare Conference, where management will deliver a corporate presentation on January 15, 2026 at 8:15 a.m. Pacific Time. A live webcast of the talk will be available through the company’s investor relations website, allowing investors to listen remotely. The associated January 2026 corporate presentation is provided as Exhibit 99.1 and is also posted in the “Overview” section of the company’s investor site.
Opus Genetics, Inc. director Cam Gallagher reported a new equity award and his current share holdings. On January 6, 2026, he received a grant of 67,000 restricted stock units (RSUs) of common stock at a price of $0. These RSUs vest on December 29, 2026, if he continues to provide service through that date.
After this grant, Gallagher beneficially owns 1,991,430 shares of Opus Genetics common stock directly. The filing also notes 83,000 shares held indirectly by him as custodian for a minor child under the Uniform Transfers to Minors Act, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.